The document provides an overview of the pharmaceutical market in Pakistan. It includes key facts and figures on the size and growth of the Pakistani pharmaceutical market, which reached PKR 343 billion in 2017. It also details the country's healthcare system structure, leading therapeutic classes, and import/export partners. The top 100 pharmaceutical companies account for over 95% of the market by both value and units. The market is growing at a projected rate of 11.42% annually.
The best brand plan any Post Graduate could prepared is here. This covers with all the aspects from competitor analysis to positioning statement to promatograms. This best brand plan can lead to your success in your career.
The best brand plan any Post Graduate could prepared is here. This covers with all the aspects from competitor analysis to positioning statement to promatograms. This best brand plan can lead to your success in your career.
The history of Clamoxyl and how Amoxicillin came in to picture. Amoxycillin, is an antibiotic useful for the treatment of a number of bacterial infections. It is the first line treatment, presented by me and my teammates
This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13
this is just powerpoint of the report on a pharma company this was to present in the class and for the ease to understand the research of principle of marketing in institute of business management IoBM
The history of Clamoxyl and how Amoxicillin came in to picture. Amoxycillin, is an antibiotic useful for the treatment of a number of bacterial infections. It is the first line treatment, presented by me and my teammates
This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13
this is just powerpoint of the report on a pharma company this was to present in the class and for the ease to understand the research of principle of marketing in institute of business management IoBM
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Role of Business Development in Pharmaceuticals (Generic Product Business)Muhammad Ali Jehangir
Role of Business Development in Pharmaceuticals (Generic Product Business)
For New Updated Slide Deck: https://www.slideshare.net/alijehangir/business-development-licensing-overview-150008616
Overview Drug, Alternative Medicines, Medical Devices Registration in PakistanMuhammad Ali Jehangir
Overview of DRAP requirement regarding Drug Manufacturing And License Fee,Drug Registration and Drug Registration Fee , Drug Pricing, Enlistment and Enlistment Fee, Medical Devices and Medical Devices Fee
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
2. phr_ali91@hotmail.com
Content
Global Pharmaceuticals Key Numbers
Pakistan Age structure, Economy
Pakistan Pharmaceutical Key Numbers
Pakistan Healthcare
Pakistan Burden of Disease
Pakistan Healthcare Structure
Pakistan Healthcare Workforce
Pakistan Healthcare Distribution system
Pakistan Leading Pharmaceuticals
Leading Therapeutic class
Leading Molecules
Leadings Brands
Product & Price
Pakistan Pharma Import & Export Partners
Pakistani Pharma Achievements
MUHAMMAD ALI 2
3. phr_ali91@hotmail.com
Global Key Numbers
Global medicine spending will reach nearly $1.5 trillion by 2021
Growth will slow from nearly 9% in 2014 and 2015 to 4–7% over the next five years
The U.S. will continue as the world’s largest pharmaceutical market and pharma emerging
markets will make up 9 of the top 20 markets with China as #2
QuintilesIMS
MUHAMMAD ALI 3
4. phr_ali91@hotmail.com MUHAMMAD ALI 4
Source: IMS Market Prognosis, Sept 2016; QuintilesIMS Institute, Oct 2016
Global Market Spending and Growth 2007–2021
9. phr_ali91@hotmail.com
Pakistan
MUHAMMAD ALI 9
o Officially Name Islamic Republic of Pakistan
o Capital Islamabad
o National languages Urdu
o Currency Pakistani rupee (₨) (PKR)
o Provinces : 4
Area: 796,095 sq km
Location:
Southern Asia, bordering the Arabian Sea, between India on the east
and Iran and Afghanistan on the west and China in the north
Time difference: UTC+5
10. phr_ali91@hotmail.com
Pakistan
Population:
204,924,861 (July 2017 est.)
Age structure:
0-14 years: 31.36% (male 33,005,623/female
31,265,463)
15-24 years: 21.14% (male 22,337,897/female
20,980,455)
25-54 years: 37.45% (male 39,846,417/female
36,907,683)
55-64 years: 5.57% (male 5,739,817/female
5,669,495)
65 years and over: 4.48% (male
4,261,917/female 4,910,094) (2017 est.)
Population growth rate:
1.4% (2017 est.)
Death rate:
6.3 deaths/1,000 population (2017 est.)
Life expectancy at birth:
total population: 67.7 years
male: 65.8 years
female: 69.8 years (2016 est.)
MUHAMMAD ALI 10
11. phr_ali91@hotmail.com
Pakistan Economy
GDP (purchasing power parity): $1.056 trillion (2017 est.)
GDP (official exchange rate): $278.9 billion (2015 est.)
GDP - real growth rate: 5.3% (2017 est.)
GDP - per capita (PPP): $5,400 (2017 est.)
Industrial production growth rate: 5% (2017 est.)
Inflation rate (consumer prices): 4.1% (2017 est.)
Exports: $21.7 billion (2017 est.)
Imports: $48.21 billion (2017 est.)
Budget:
Revenues: $45.64 billion
Expenditures : $59.28 billion
Exchange rates: Pakistani rupees (PKR) per US dollar -105 (FY2017 est.)
MUHAMMAD ALI 11
12. phr_ali91@hotmail.com
Pakistan Pharmaceutical Overview
Total Registered Pharmaceutical in Pakistan approximately 775
Multinational Pharmaceutical Company 26
National Pharmaceutical Company 749
Estimated size of the Pharmaceutical market is Pkr 343 Billion (IMS Q4, 2017)
Projected Growth of Market is 11.42% in 2018
Molecules 2,200 plus
1% of profit of All Registered Pharmaceutical to MOH for R&D Expenditure
This again makes the country the region's 7th most attractive market in Asia.
MUHAMMAD ALI 12
13. phr_ali91@hotmail.com
Pakistan Key Numbers (2017 Fact & Figures)
Top 100 Pharmaceuticals have 97% share of market value wise
Rest of 600 plus Pharmaceuticals contributes only 2.93% value wise
Top 100 Pharmaceuticals have 96% share of market unit wise
Rest of 600 plus Pharmaceuticals contributes only 4% unit wise
Top 100 Molecule have 61% of Market share
Rest of others Molecules contribute 39%
Top 100 Brands have 33% of Market share
Rest of others Brands contribute 67%
Top 10 Therapeutic class (ATC I) have 93 % share of market , rest 6 therapeutic class have 7% of share.
2017 New Launches contributes Pkr 2 billion
MUHAMMAD ALI 13
15. phr_ali91@hotmail.com
Pakistan Healthcare
Health expenditures: 2.6% of GDP (2014)
Physicians density: 0.81 physicians/1,000 population (2014)
Hospital bed density: 0.6 beds/1,000 population (2012)
Major infectious diseases:
Degree of risk: high
Food or waterborne diseases: bacterial diarrhea, hepatitis A and E, and typhoid fever
Vector borne diseases: dengue fever and malaria
Animal contact disease: rabies (2016)
MUHAMMAD ALI 15
20. phr_ali91@hotmail.com
Key Health Numbers, 2014 by IFPMA & WHO
Country
LIFE
EXPECTAN
CY AT
BIRTH
(YEARS)
LIFE
EXPECTAN
CY AT
AGE 60
(YEARS)
CHILD
MORTALIT
Y (PER
1,000
BIRTHS)
PHYSICIAN
S (PER
1,000
PEOPLE)
TOTAL
HEALTH
EXPENDIT
URE PER
CAPITA
(USD PER
CAPITA)
TOTAL
HEALTHCA
RE
EXPENDIT
URE
(%GDP)
PUBLIC
HEALTHCA
RE
EXPENDIT
URE
(%GDP)
OUT-OF-
POCKET
HEALTH
EXPENDIT
URE (% OF
PRIVATE
HEALTH
EXPENDIT
URE)
Pakistan 66,18 17,80 67,40 0,83 128,99 2,61 0,92 86,79
India 68,01 17,80 39,30 0,70 267,41 4,69 1,41 89,21
Bangladesh
71,63 18,80 32,10 0,36 88,08 2,82 0,79 92,89
MUHAMMAD ALI 20
21. phr_ali91@hotmail.com
Healthcare System Structure
MUHAMMAD ALI 21
Health Manpower 2013-2014 2014-2015 2015-2016
Hospitals 1,113 1,143 1,167
Dispensaries 5,413 5,548 5,695
Basic Health Units
Centers
5,571 5,438 5,464
Maternity & Child health
Centers
687 670 733
Rural Health Centers 667 669 675
TB Centers 329 334 339
Total Beds 118,378 118,170 118,869
Source: Ministry of Health, Planning Commission of Pakistan, Pakistan Bureau of Statistics
22. phr_ali91@hotmail.com
Healthcare System Structure
MUHAMMAD ALI 22
Hospitals
Dispensaries
Maternity & Child
welfare centers
Beds in hospitals
& dispensaries
etc.
Federal 9 83 3 2523
Punjab 368 1325 280 57648
Sindh 427 2912 221 33774
Khyber
Pakhtunkhwa/
FATA
270 915 131 21908
Baluchistan 127 567 96 7541
Sources:- i) Health Division ii) Provincial Health Directorates. 2016
23. phr_ali91@hotmail.com
Health systems by World health statistics 2015. WHO
Density of health workforce (per 10 000 population)
Country Physicians
Nursing and
midwifery
personnel
Dentistry
personnel
Psychiatrists Hospitals
Psychiatric
beds
Pakistan 8.3 5.7 0.6 <0.05 0.5 5.6
India 7.0 17.1 1.0 <0.05 -- 2.1
Bangladesh 3.6 2.2 0.3 <0.05 0.2 3.5
MUHAMMAD ALI 23
24. phr_ali91@hotmail.com
Healthcare Workforce
MUHAMMAD ALI 24
Health Manpower 2013-2014 2014-2015 2015-2016
Registered Doctors 167,759 175,223 184,711
Registered Dentists 13,716 15,106 16,652
Registered Nurses 86,183 90,276 94,766
Registered Midwives 32,677 33,687 34,668
Registered Lady Health
Visitor
14,388 15,325 16,448
Pakistan Bureau of Statistics
25. phr_ali91@hotmail.com MUHAMMAD ALI 25
STATISTICS
TOTAL NUMBER OF DOCTORS / DENTAL SURGEONS (G.P's with basic degree only)
TOTAL NUMBER OF DOCTORS/DENTAL
SURGEONS REGISTERED
REGISTERED UP TO 31st DECEMBER, 2016
Up to 31st DECEMBER, 2016 AS
SPECIALISTS
M.B.B.S. B.D.S. L.S.M.F. M.B.B.S. B.D.S.
Province Total Total Total Total Total
Punjab/Federal Area 67486 7157 565 19015 731
Sindh 60315 6055 306 10996 450
K.P.K 19751 2626 54 5283 349
Baluchistan 4481 470 55 1290 49
A.J.K. 3229 331 4 879 38
Foreign Nationals 3812 486 106 110 4
Total 159074 17125 1090 37573 1621
TOTAL=159074+17125+1090= 177289
TOTAL LSMF=1090
TOTAL RMPs (Basic & Specialists)=(159074+37573)=196647
TOTAL RDPs (Basic & Specialists)=(17125+1621)=18746
GRAND TOTAL=196647+18746+1090=216483
GRAND TOTAL=RMP+RDP+LSMF
http://www.pmdc.org.pk/Statistics/tabid/103/Default.aspx
26. phr_ali91@hotmail.com
Doctor Universe Pakistan
General Practitioner , 27000
Physician, 4250
Pediatrcian, 2800
Cardiologict, 1200
Gynaecologist, 5000
Orthopaedician, 1000 Surgeon, 3000
MUHAMMAD ALI 26
Estimated Doctor Universe >65,000 Estimated Chemist Universe >45,000
27. phr_ali91@hotmail.com
Manufacturers & Importers
Distributors
89.97 %
Govt
Institutional
6.71%
Export 2.26%
Direct to
Doctors .77%
Direct to
patients .17%
Others .12%
Retail Pharmacies
59.25%
Wholsellers
29.16%
Doctors 3.75%
Private hospitals
2.60%
Others 3.45%
Govt Hospitals
1.79%
Channels of Distribution
MUHAMMAD ALI 27
28. phr_ali91@hotmail.com
Wholesale, Distributors & Pharmacies Universe
MUHAMMAD ALI 28
ENTIRE COUNTRY
Total Wholesale 4,443
Total Distributors 1,045
Normal Pharmacies 47,139
Private Hospital Pharmacies & Vicinity Pharmacies 11,222
Total Pharmacies 58,541
29. phr_ali91@hotmail.com
4 Year Total Pharmaceutical Market
MUHAMMAD ALI 29
Therapeutic Class Value in Pkr
Growth
(%)
2017 343,936,385,875 6.14
2016 324,042,332,978 15.64
2015 280,218,511,653 13.37
2014 247,164,343,362 11.72
31. phr_ali91@hotmail.com
MNC vs National
MUHAMMAD ALI 31
Value Unit Growth Share
SELECTED TOTAL 343,936,385,875 2,604,859,276 6.14 100.00
NATIONAL 230,926,595,115 1,697,926,063 7.67 67.14
MULTI-NATIONAL 113,009,790,760 906,933,213 3.14 32.86
32. phr_ali91@hotmail.com MUHAMMAD ALI 32
Leading Pharmaceutical Companies in Pakistan (Value Wise)
No. Name of the Manufacturer Value in Pkr Growth % Contribution %
Total 343,936,385,875 6.14 100.00
1 GLAXOSMITHKLINE 25,425,036,049 2.00 7.39
2 ABBOTT LAB PAK LTD 21,632,085,556 9.80 6.29
3 GETZ PHARMA 21,426,456,299 12.44 6.23
4 SAMI 18,028,510,063 9.03 5.24
5 MARTIN DOW LIMITED 14,280,245,205 13.33 4.15
6 THE SEARLE COMPANY 12,711,429,200 10.07 3.70
7 SANOFI-AVENTIS PAK 10,651,356,774 -2.06 3.10
8 OBS 10,263,419,074 1.33 2.98
9 GSK CONSUMER 10,237,998,715 14.80 2.98
10 HILTON 10,129,279,248 7.11 2.95
11 HIGH-Q INTL 9,831,053,211 24.35 2.86
12 BOSCH 9,597,149,040 8.84 2.79
13 PFIZER INC 9,218,802,077 3.70 2.68
14 NOVARTIS PH.PAK LT 9,133,307,529 -2.79 2.66
15 BARRETT HODGSON 7,031,661,852 10.05 2.04
16 ATCO 6,302,664,054 8.75 1.83
17 BAYER PAK PVT LTD 6,012,092,180 15.58 1.75
18 NESTLE PAKISTAN LT 5,690,343,085 -2.96 1.65
19 HIGHNOON 5,666,460,293 15.65 1.65
20 PHARMEVO PVT. LTD. 5,524,056,416 29.87 1.61
33. phr_ali91@hotmail.com MUHAMMAD ALI 33
Leading Pharmaceutical Companies in Pakistan (Unit Wise)
No. Name of the Manufacturer Unit or Volume Growth % Contribution %
TOTAL 2,604,859,276 2.53 100.00
1 GLAXOSMITHKLINE 334,661,875 -4.98 12.85
2 ABBOTT LAB PAK LTD 188,944,872 7.25 7.25
3 SAMI 132,876,531 5.06 5.10
4 THE SEARLE COMPANY 114,619,830 10.23 4.40
5 MARTIN DOW LIMITED 105,285,359 3.12 4.04
6 GSK CONSUMER 101,437,395 7.56 3.89
7 GETZ PHARMA 100,922,328 10.68 3.87
8 BOSCH 75,315,211 6.20 2.89
9 SANOFI-AVENTIS PAK 73,877,666 -5.65 2.84
10 BARRETT HODGSON 69,851,136 6.90 2.68
11 ATCO 68,774,862 6.06 2.64
12 OBS 58,945,905 4.94 2.26
13 I.C.I 55,718,137 -16.32 2.14
14 HIGHNOON 47,228,536 11.78 1.81
15 HIGH-Q INTL 46,883,813 23.63 1.80
16 PFIZER INC 41,625,402 0.75 1.60
17 NABIQASIM 38,487,643 2.63 1.48
18 NOVARTIS PH.PAK LT 37,541,000 -10.88 1.44
19 HILTON 37,490,043 4.77 1.44
20 NESTLE PAKISTAN LT 30,763,677 -2.02 1.18
34. phr_ali91@hotmail.com MUHAMMAD ALI 34
Leading Pharmaceutical Companies (New Launches Wise)
No. Name of the Manufacturer Value No of Products PPY
1 MACTER 245,027,604 2 122,513,802
2 THE SEARLE COMPANY 137,796,214 12 11,483,018
3 SAMI 128,374,514 4 32,093,629
4 HIGH-Q INTL 121,440,288 5 24,288,058
5 OBS 119,516,048 14 8,536,861
6 GETZ PHARMA 115,577,411 6 19,262,902
7 ATCO 110,877,596 8 13,859,700
8 CCL 103,749,303 8 12,968,663
9 WILSHIRE 71,311,275 2 35,655,638
10 FEROZSONS 67,739,275 2 33,869,638
11 WILSONS 55,870,085 2 27,935,043
12 GENIX PHARMA 55,488,435 9 6,165,382
13 PHARMEVO PVT. LTD. 44,449,950 3 14,816,650
14 I.C.I 41,325,921 4 10,331,480
15 ASIAN CONTINENTAL 39,913,533 3 13,304,511
16 FYNK PHARMA 38,495,524 1 38,495,524
17 S.J.& G. FAZUL 35,846,165 3 11,948,722
18 HIGHNOON 33,355,324 6 5,559,221
19 TABROS PHARMA 32,649,529 6 5,441,588
20 SCILIFE 27,080,321 5 5,416,064
35. phr_ali91@hotmail.com MUHAMMAD ALI 35
0
50,000,000
100,000,000
150,000,000
200,000,000
250,000,000
300,000,000
Leading Pharmaceutical Companies (New Launches Wise)
Value PPY
36. phr_ali91@hotmail.com MUHAMMAD ALI 36
Therapeutic Categories in Pakistan
No. Therapeutic Class Value in Pkr
Growth
(%)
Share
(%)
1 ALIMENTARY T.& METABOLISM 81,767,949,980 12.25 23.77
2 SYSTEMIC ANTI-INFECTIVES 75,516,779,937 -0.43 21.96
3 NERVOUS SYSTEM 31,518,438,716 12.07 9.16
4 CARDIOVASCULAR SYSTEM 25,620,352,283 10.94 7.45
5 MUSCULO-SKELETAL SYSTEM 25,108,143,417 8.75 7.30
6 RESPIRATORY SYSTEM 24,699,344,924 3.37 7.18
7 VARIOUS 20,890,548,241 1.40 6.07
8 DERMATOLOGICALS 12,352,518,001 13.26 3.59
9 BLOOD + B.FORMING ORGANS 12,068,777,766 4.17 3.51
10 G.U.SYSTEM & SEX HORMONES 10,629,827,853 12.27 3.09
11 SENSORY ORGANS 6,614,460,812 11.78 1.92
12 PARASITOLOGY 6,610,900,640 -1.65 1.92
13 ANTINEOPLAST+IMMUNOMODUL 3,423,773,439 -32.66 1.00
14 HOSPITAL SOLUTIONS 3,135,839,799 4.97 0.91
15 SYSTEMIC HORMONES 2,978,745,067 0.51 0.87
16 DIAGNOSTIC AGENTS 999,985,000 8.65 0.29
37. phr_ali91@hotmail.com MUHAMMAD ALI 37
Therapeutic Categories In Pakistan And Their Share
ALIMENTARY T.& METABOLISM
24%
SYSTEMIC ANTI-INFECTIVES
22%
NERVOUS SYSTEM
9%
CARDIOVASCULAR SYSTEM
7%
MUSCULO-SKELETAL SYSTEM
7%
RESPIRATORY SYSTEM
7%
VARIOUS
6%
DERMATOLOGICALS
4%
BLOOD + B.FORMING ORGANS
4%
G.U.SYSTEM & SEX HORMONES
3%
SENSORY ORGANS
2%
PARASITOLOGY
2%
ANTINEOPLAST+IMMUNOMODUL
1%
HOSPITAL
SOLUTIONS
1%
SYSTEMIC HORMONES
1%
DIAGNOSTIC AGENTS
0%
41. phr_ali91@hotmail.com
The Product
The Product Pharmaceutical products are used in the treatment of diseases hence called “Drug”
Every operation pertaining to the drugs including import, manufacturing & distribution is
governed by “The Drugs Act 1976”.
The Product Drugs are manufactured under the strict quality standards called GMP (good
manufacturing practices)
No product can be marketed/distributed unless registered by the Ministry of Health, Pakistan
MUHAMMAD ALI 41
42. phr_ali91@hotmail.com
The Price
The key factor affecting the price of drugs include but not limited to
Uniqueness (availability) of the product
The country from where final dosage form or the main raw materials are imported
Process steps involved in manufacturing
Size of production (economies of scale)
MUHAMMAD ALI 42
43. phr_ali91@hotmail.com
The Price
Price structure Cost of raw/packaging materials
Cost of conversion
Cost of distribution
• Distributor margin
• Retailer margin
Cost of promotion
The cost of drugs is higher than the profits associated with them
MUHAMMAD ALI 43
44. phr_ali91@hotmail.com
Mark Up Components Of Drug Pricing Policy 2015
MUHAMMAD ALI 44
MRP to be applied Pack size
TP 15% Less
DP 8% Less
Manufacturing Cost - COGS 30%
Product Development & Stability 3%
Product Expiry 2%
Warehouse and Cold Chain 2%
Salesman salaries and travel 10%
Sales Promotion 3%
Samples 3%
General Administration 4%
Financial Charges 3%
WPPF & CRF 1%
Income Tax 8%
Distribution exp. & Discount 16%
Manufacturer Profit 15%
Total 100%
45. phr_ali91@hotmail.com
Major Trading Partners of Pakistan in
Pharmaceutical Products
Major Import Counties
India
China
European Countries (Denmark, Switzerland, Germany, Belgium, Italy, Sweden )
Major Export Regions
Afghanistan, Sri Lanka
ASEAN Countries (Vietnam, Philippines, Laos, Cambodia, Myanmar)
CIS Countries (Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan)
African Countries (Burundi, Cote d'Ivoire, Ethiopia, Ghana, Kenya, Malawi, Rwanda, Senegal, Somalia,
Sudan, Uganda)
MUHAMMAD ALI 45
48. phr_ali91@hotmail.com
New Achievements of Pakistani Pharma
Pacific Pharma got MHRA Approved Plant.
Getz Pharma got WHO qualification for their Plant.
Martin Dow acquired 2 pharmaceutical manufacturing facility in France.
MUHAMMAD ALI 48
49. phr_ali91@hotmail.com
References
Pakistan Demography Profile from World fact book
Quintiles IMS Institute (Q4, 2017)
Healthcare System Structure data obtained from
PMDC website
i) Health Division. ii) Provincial Health Directorates.
IFPMA Fact & Figures 2017
WHO World Health Statistics 2015 & 2016
Health and Nutrition - Ministry of Finance 2016
The Institute for Health Metrics and Evaluation (IHME) (Pakistan Profile)
MUHAMMAD ALI 49
50. phr_ali91@hotmail.com
Presentation
For further presentation related to pharmaceutical sales and marketing visit my blog
www.phrali.blogspot.com
Some of my presentation are
How to make Marketing Plan for Pharmaceutical Product
Pharmaceuticals Marketing Strategies
Pharmaceutical Sales in Pakistan
Marketing and Sales roles in the pharmaceutical industry
New Launch Strategy & Product Cycle
Role of Business Development in Pharmaceuticals (Generic Market)
MUHAMMAD ALI 50